Financial Contrast: Jaguar Health (JAGX) versus Zosano Pharma (ZSAN)
Jaguar Health (NASDAQ:JAGX) and Zosano Pharma (NASDAQ:ZSAN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.
Earnings & Valuation
This table compares Jaguar Health and Zosano Pharma’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Jaguar Health||$4.36 million||3.62||-$21.96 million||N/A||N/A|
|Zosano Pharma||N/A||N/A||-$29.10 million||N/A||N/A|
This table compares Jaguar Health and Zosano Pharma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
5.0% of Jaguar Health shares are held by institutional investors. Comparatively, 34.0% of Zosano Pharma shares are held by institutional investors. 3.4% of Jaguar Health shares are held by company insiders. Comparatively, 0.7% of Zosano Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Risk and Volatility
Jaguar Health has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Zosano Pharma has a beta of 2.28, meaning that its share price is 128% more volatile than the S&P 500.
This is a breakdown of current ratings and target prices for Jaguar Health and Zosano Pharma, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Zosano Pharma has a consensus price target of $19.00, suggesting a potential upside of 771.56%. Given Zosano Pharma’s higher possible upside, analysts plainly believe Zosano Pharma is more favorable than Jaguar Health.
Zosano Pharma beats Jaguar Health on 6 of the 10 factors compared between the two stocks.
About Jaguar Health
Jaguar Health, Inc., a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its human health product pipelines include Mytesi, which is Phase II clinical trial for the treatment of cancer therapy-related diarrhea, as well as for the supportive care for inflammatory bowel disease; formulation of crofelemer that is Phase II clinical trial for the treatment of short bowel syndrome, congenital diarrheal disorders, and irritable bowel syndrome – diarrhea predominant diseases; and SB-300, a second-generation anti-secretory agent for multiple indications, including cholera. The company's animal health product candidates comprise Canalevia, an animal prescription drug product candidate intended for treatment of various forms of diarrhea in dogs; and Equilevia is Jaguar's non-prescription product for total gut health in equine athletes. In addition, the company's products include Neonorm Calf and Neonorm Foal. Jaguar Health, Inc. is headquartered in San Francisco, California.
About Zosano Pharma
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.
Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.